Literature DB >> 22821657

Effect of oxymatrine on hepatic gene expression profile in experimental liver fibrosis of rats.

Yi-cheng Jian1, Wei Li, Yi He, Ming Jiang, Yan-bing Liu, Wu-jun Xiong.   

Abstract

OBJECTIVE: To investigate the effects of oxymatrine on hepatic gene expression profile in a rat model of liver fibrosis.
METHODS: Forty healthy male SD rats were randomly divided into three groups, a normal group (n=8), a model group (n=16), and an oxymatrine treatment group (n=16). Experimental hepatic fibrosis was induced by subcutaneous injection of carbon tetrachloride (CCl(4)). The rats in the treatment group received oxymatrine via celiac injection at a dosage of 40 mg/kg once a day at the same time. The rats in the model and normal groups received saline at the same dosage via celiac injection. Serum levels of aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (AKP), hyaluronic acid (HA), and laminin (LN) were assayed. The deposition of collagen was observed with HE and Masson staining. Effect of oxymatrine on hepatic gene expression profile was detected by oligonucleotide microarray analysis with Affymetrix gene chip rat U230A. Quantitative real-time polymerase chain reaction (QRT-PCR) was carried out to confirm the expression changes of six genes.
RESULTS: Oxymatrine significantly improved liver function, lowered serum levels of HA and LN, and decreased the degree of liver fibrosis, compared with the model group (P<0.05). A total of 754 differentially expressed genes were identified by gene chip between the model group and the normal group, among which 438 genes increased and 316 genes decreased over two folds. Compared with the model group, 86 genes were downregulated markedly in the oxymatrine group (P<0.05), including collagen I and other genes related to extracellular material (ECM), integrin signal transduction genes, early growth response factor genes, and proinflammatory genes; 28 genes were upregulated significantly (P<0.05), including cytochrome P450 (CYP450) superfamily genes, glycolipids metabolism and biological transformation related genes. Six genes were confirmed with QRT-PCR, consistent with the result from microarray.
CONCLUSION: Oxymatrine could affect the expression of many functional genes and may be useful in the prevention and treatment of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821657     DOI: 10.1007/s11655-012-1115-x

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  16 in total

1.  Immunomodulatory effect of oxymatrine on induced CCl4-hepatic fibrosis in rats.

Authors:  Xiao-hu Yu; Jin-shui Zhu; Hua-fang Yu; Li Zhu
Journal:  Chin Med J (Engl)       Date:  2004-12       Impact factor: 2.628

2.  Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-alpha.

Authors:  Chun-Song Wu; Xi-Xu Piao; Dong-Ming Piao; Yong-Ri Jin; Cheng-Hao Li
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 3.  Classification of chronic viral hepatitis: a need for reassessment.

Authors:  P J Scheuer
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

4.  Effect of oxymatrine on the p38 mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis.

Authors:  Zi-Yu Deng; Jun Li; Yong Jin; Xiao-Liang Chen; Xiong-Wen Lü
Journal:  Chin Med J (Engl)       Date:  2009-06-20       Impact factor: 2.628

5.  Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats.

Authors:  J P Zhang; M Zhang; J P Zhou; F T Liu; B Zhou; W F Xie; C Guo
Journal:  Acta Pharmacol Sin       Date:  2001-02       Impact factor: 6.150

6.  Early growth response factor-1 is critical for cholestatic liver injury.

Authors:  Nam Deuk Kim; Jeon-Ok Moon; Angela L Slitt; Bryan L Copple
Journal:  Toxicol Sci       Date:  2006-01-19       Impact factor: 4.849

7.  Effects of oxymatrine on experimental hepatic fibrosis and its mechanism in vivo.

Authors:  Guang-Feng Shi; Qian Li
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

8.  Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study.

Authors:  Yi-Min Mao; Min-De Zeng; Lun-Gen Lu; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chuen Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  Inhibition of the replication of hepatitis B virus in vitro by oxymatrine.

Authors:  M Lin; L Y Yang; W Y Li; Y P Peng; Jia-Kun Zheng
Journal:  J Int Med Res       Date:  2009 Sep-Oct       Impact factor: 1.671

Review 10.  Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials.

Authors:  Jianping Liu; Eric Manheimer; Kiichiro Tsutani; Christian Gluud
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

View more
  3 in total

1.  Effects of Ganfukang on expression of connective tissue growth factor and focal adhesion kinase/protein kinase B signal pathway in hepatic fibrosis rats.

Authors:  Kun Zhang; Miao-na Jiang; Cai-hua Zhang; Cong Li; Yu-jie Jia
Journal:  Chin J Integr Med       Date:  2013-08-29       Impact factor: 1.978

Review 2.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

3.  Astragalus and Paeoniae Radix Rubra extract (APE) inhibits hepatic stellate cell activation by modulating transforming growth factor-β/Smad pathway.

Authors:  Weijuan Huang; Lin Li; Xiaopeng Tian; Jinjin Yan; Xinzheng Yang; Xinlong Wang; Guozhen Liao; Genquan Qiu
Journal:  Mol Med Rep       Date:  2014-12-01       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.